To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Metastatic Breast Cancer

Lauren M. Green
People across the nation are participating in the Metastatic Breast Cancer (MBC) Project to help researchers steer the approach in fighting the disease.  
Anita T. Shaffer
Recent findings may make way for a less expensive treatment option for patients with metastatic breast cancer. 
Silas Inman
Postmenopausal women with locally-advanced or metastatic HR-positive breast cancer benefited from the use of Faslodex (fulvestrant) as a frontline treatment. 
Ann Silberman
Five years ago, I was stricken with metastatic breast cancer. This heartbreaking diagnosis came not long after I finished treatment for early stage, HER2+ cancer.
Andrew J. Roth
O’Shaughnessy highlighted a group of agents that encompasses entirely new ideas and new options for patients as well as novel avenues from follow-up data from clinical trials.
Andrew J. Roth
CURE speaks with Joyce O’Shaughnessy, MD, on the rise of treatment options for patients with estrogen receptor (ER)-positive metastatic breast cancer.
Debu Tripathy
In this issue of CURE magazine, we review the current approaches for the evaluation and treatment of metastatic breast cancer, and what the future holds.
Silas Inman
After a median follow-up of 10 months, the overall response rate in patients with PD-L1-expressing metastatic breast cancer was 33.3 percent.
An academically trained skeptic, this single project has turned me into a raving optimist.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment


Healthcare Professional

Not Applicable